Table 3.

Response Rates and % Subjects with rSBA Titers ≥ 128 by Serogroup for Subjects with Data at Weeks 0, 4, 24, 28 and 72

SG	Group	≥4-fold increase in rSBA titer at Week 4*	≥4-fold increase in rSBA titer at Week 28*	% (n/N) Subjects with rSBA titer ≥ 128					% (n/N) Subjects with rSBA titer ≥ 8
				Baseline	Week 4	Week 24	Week 28	Week 72	Week 28	Week 72
A	Group 1: 1-Dose	75% (83/110)	45% (49/110)	43% (47/110)	87% (96/110)	70% (77/110)	66% (73/110)	57% (54/95)	68% (75/110)	59% (56/95)
	Group 1: 2-Doses	76% (85/112)	72% (81/112)	38% (43/112)	91% (102/112)	68% (76/111)	88% (99/112)	71% (67/95)	88% (99/112)	76% (72/95)
	Group 2	25% (5/20)	40% (8/20)	35% (7/20)	60% (12/20)	35% (7/20)	55% (11/20)	22% (4/18)	60% (12/20)	28% (5/18)
C	Group 1: 1-Dose	62% (67/108)	34% (37/108)	14% (15/108)	65% (70/108)	35% (37/107)	31% (33/108)	21% (19/92)	42% (45/108)	24% (22/92)
	Group 1: 2-Doses	59% (66/112)	69% (77/112)	9% (10/112)	59% (66/112)	30% (33/111)	64% (72/112)	35% (34/96)	72% (81/112)	49% (47/96)
	Group 2	17% (3/18)	17% (3/18)	6% (1/18)	22% (4/18)	17% (3/18)	22% (4/18)	6% (1/16)	22% (4/18)	13% (2/16)
W- 135	Group 1: 1-Dose	83% (91/109)	72% (79/109)	17% (19/109)	83% (91/109)	76% (83/109)	72% (79/109)	60% (56/94)	79% (86/109)	69% (65/94)
	Group 1: 2-Doses	82% (93/113)	86% (97/113)	16% (18/113)	78% (88/113)	67% (75/112)	86% (97/113)	66% (63/96)	89% (100/113)	77% (74/96)
	Group 2	32% (6/19)	42% (8/19)	0% (0/19)	21% (4/19)	16% (3/19)	26% (5/19)	6% (1/17)	42% (8/19)	24% (4/17)
Y	Group 1: 1-Dose	69% (75/109)	59% (64/109)	38% (41/109)	83% (90/109)	79% (86/109)	74% (81/109)	63% (59/94)	82% (89/109)	80% (75/94)
	Group 1: 2-Doses	64% (74/115)	75% (86/115)	33% (38/115)	73% (84/115)	71% (81/114)	83% (96/115)	71% (70/98)	91% (105/115)	84% (82/98)
	Group 2	40% (8/20)	40% (8/20)	5% (1/20)	30% (6/20)	30% (6/20)	30% (6/20)	28% (5/18)	45% (9/20)	28% (5/18)

^*Compared with entry